Answers are grounded in this paper and cite their sources.
Antiasthmatic activity of carbamazepine and sodium valproate was investigated in 28 patients (open-label trial) with moderate and severe bronchial asthma. Stable and complete remission was achieved in 10 patients of the carbamazepine group (n=14), and in 11 patients of the sodium valproate group (n=14). A follow-up study showed high and stable antiasthmatic efficacy of carbamazepine or sodium valproate monotherapy. Based on the high efficacy of these anticonvulsants in patients with bronchial asthma we suppose that bronchial asthma can be considered as mainly neurogenic paroxysmal and inflammatory disease.
No takes yet. Share an insight, caveat, or question.
A 2005 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: